Chemical Property of Javlor
Chemical Property:
- Refractive Index:1.652
- PKA:11.36±0.60(Predicted)
- PSA：133.87000
- Density:1.39 g/cm3
- LogP:5.01950
- XLogP3:4.4
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:13
- Rotatable Bond Count:10
- Exact Mass:816.39097102
- Heavy Atom Count:59
- Complexity:1720
- Purity/Quality:
-
99% *data from raw suppliers
Vinflunine 98+% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C
- Isomeric SMILES:CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(C[C@H]7C[C@H](CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C
- Recent ClinicalTrials:A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- Recent EU Clinical Trials:A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
- Recent NIPH Clinical Trials:None
-
Description
Vinflunine (also referred to as PM391) is a semisynthetic analog of the
natural vinca alkaloids vinblastine and vincristine that was approved by
the European Medicines Agency (EMEA) in 2009 for the treatment of
adult patients with advanced or metastatic transitional cell carcinoma of
the urothelial tract after failure of a prior platinum-containing regimen.
Vinflunine is synthesized from anhydrovinblastine in a
superacid media (HF-SbF5) and in the presence of a chlorinated solvent
like CHCl3 or CCl4.
-
Clinical Use
Antineoplastic agent (vinca alkaloid): Treatment of advanced or metastatic bladder cancer
-
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: possible increased risk of ventricular
arrhythmias with delamanid; concentration possibly
reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by
St Johns wort - avoid.
Antifungals: concentration increased by ketoconazole
and possibly itraconazole (increased risk of
neurotoxicity) - avoid.
Antimalarials: avoid with piperaquine with
artenimol.
Antipsychotics: avoid with clozapine (increased risk
of agranulocytosis).
Antivirals: concentration possibly increased by
ritonavir - avoid.
Grapefruit juice: concentration of vinflunine
increased - avoid.
